Tang H, et al. - After a systematic search of electronic databases up to May 2, 2018, researchers performed a meta-analysis of 21 randomized controlled trials comprising 20,816 subjects to determine the relationship between sodium-glucose cotransporter 2 (SGLT2) inhibitors and risk of skin cancer among patients with type 2 diabetes. The results obtained from the study did not support a significantly increased risk of skin cancer correlated with SGLT2 inhibitors.